# Altimmune, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Altimmune, Inc.). ## Overview Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing therapies for serious liver diseases. Its lead candidate, pemvidutide, is a balanced 1:1 glucagon/GLP-1 dual receptor agonist being studied for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company is still in the development stage and has not generated product sales to date, so its business model depends on advancing clinical programs, securing financing, and potentially partnering or monetizing assets. Altimmune is headquartered in Gaithersburg, Maryland and trades on Nasdaq under the symbol ALT. ## Products & services • Pemvidutide for MASH • Pemvidutide for alcohol use disorder (AUD) • Pemvidutide for alcohol-associated liver disease (ALD) • Additional pemvidutide indications • Clinical development and trial execution - **Lead drug candidate development** (90%) — Clinical development of pemvidutide across liver disease and metabolic indications. - **Pipeline expansion** (10%) — Evaluation of additional indications that could leverage pemvidutide's clinical profile. - Pemvidutide for MASH - Pemvidutide for alcohol use disorder (AUD) - Pemvidutide for alcohol-associated liver disease (ALD) - Additional pemvidutide indications - Clinical development and trial execution ## Customers Altimmune does not sell approved commercial products, so its primary 'customers' are not end-market patients but rather the stakeholders that enable drug development. The company relies on clinical trial participants, investigators, contract research organizations, manufacturers, and other third-party service providers to advance pemvidutide through development. If the program succeeds, future buyers would likely be pharmaceutical partners, licensees, or ultimately healthcare providers and payers supporting patient access. In the near term, value creation depends on generating clinical data that can attract partnership interest and support regulatory progress. - **Clinical trial ecosystem** (primary) — Patients, investigators, CROs, and vendors involved in running pemvidutide studies for MASH, AUD, and ALD. - **Strategic pharmaceutical partners** (primary) — Potential collaborators or acquirers that may fund, license, or commercialize pemvidutide if clinical data are compelling. - **Future prescribers and payers** (emerging) — Healthcare providers and reimbursement decision-makers that would matter only if pemvidutide reaches approval and market launch. - Clinical trial participants enrolled in MASH, AUD, and ALD studies - Investigators and trial sites that run the clinical programs - CROs and vendors that support development and manufacturing - Potential pharma partners or licensees for pemvidutide - Future healthcare providers and payers if a product is approved ## Geography Altimmune is headquartered in the United States and its principal operations are managed from Maryland. The company has conducted clinical trials in the U.S. and other countries, and it notes that future trials may also occur in the United Kingdom, the European Union, or other foreign jurisdictions. Its reported consolidated entities include Altimmune UK, Ltd and Altimmune AU Pty, Ltd, indicating an international operating footprint even though the business remains U.S.-centered. Geography matters mainly because clinical development depends on regulatory approvals, site activation, patient enrollment, and supply-chain execution across jurisdictions. The company also highlighted tariff, inflation, and foreign-exchange-related uncertainty as factors that can affect operations and costs. - **United States** (100%) — No country-level revenue disclosure; company is U.S.-based and operations are primarily U.S.-centered. - Headquartered in Gaithersburg, Maryland, United States - Nasdaq-listed U.S. biopharma with U.S.-centered operations - Clinical trials may be run in the U.K. and EU - Foreign trial execution adds regulatory and enrollment complexity - Tariffs, inflation, and FX can affect trial and supply costs ## Strategy Altimmune's strategy is centered on advancing pemvidutide through late-stage clinical development in MASH while also building optionality in AUD and ALD. The company is trying to differentiate the asset through a balanced glucagon/GLP-1 mechanism and a clinical profile that could support multiple liver-related indications. Because it has no product revenue, capital allocation is focused on preserving runway, funding trials, and maintaining flexibility to partner or monetize programs. Management also appears to be broadening the value proposition by evaluating additional indications that could reuse the same molecule and development infrastructure. - **Complete and read out late-stage pemvidutide trials** (short-term) — Clinical data are the main source of value because the company has no commercial revenue. - **Expand pemvidutide into multiple liver disease indications** (medium-term) — A broader label opportunity could improve partnering leverage and commercial potential. - **Secure external funding and strategic partnerships** (short-term) — Long-duration clinical development requires capital beyond current cash resources. - Advance pemvidutide in MASH as the lead value driver - Develop AUD and ALD programs to broaden the addressable market - Use a differentiated dual-receptor mechanism to stand out clinically - Preserve cash runway through disciplined trial and overhead spending - Pursue partnerships or asset monetization to fund long-term needs - Evaluate additional indications that leverage the same molecule ## Risks Altimmune faces the classic risks of a single-asset, late clinical-stage biotech company: trial failure, delayed enrollment, regulatory setbacks, and dependence on external financing. The company specifically notes that if it cannot maintain strategic partnerships for pemvidutide, it may have to bear the full cost and risk of development, which would pressure capital needs. It also faces operational risk from third-party vendors, foreign trial jurisdictions, and macro factors such as tariffs, inflation, supply-chain disruption, and capital-market volatility. More broadly, competition from much larger pharmaceutical companies could make it harder to recruit patients, secure manufacturing capacity, and ultimately commercialize a product if one is approved. - **Single-asset clinical development risk** [critical] — Most of the company's value is tied to pemvidutide, so adverse trial results or safety issues would have an outsized impact. - **Financing and dilution risk** [high] — The company has no product revenue and must continue raising capital to fund trials and operations. - **Regulatory and trial execution risk** [high] — Clinical timelines depend on FDA and foreign regulatory reviews, site activation, and patient enrollment. - **Competitive pressure from large pharmaceutical companies** [high] — Large incumbents have greater R&D, manufacturing, and commercialization resources in overlapping therapeutic areas. - **Supply-chain and macro cost inflation** [medium] — Tariffs, inflation, and logistics disruptions can increase clinical and manufacturing costs. - Pemvidutide clinical failure would materially reduce company value - Dependence on external financing creates dilution and runway risk - Partnership shortfalls could force Altimmune to fund development alone - Third-party CRO and manufacturing disruptions can delay trials - Regulatory delays from FDA or foreign authorities can slow approvals - Large pharma competition may outspend Altimmune in development and commercialization - Inflation, tariffs, and supply-chain issues can raise trial costs ## Accounting Altimmune's accounting profile is dominated by development-stage judgments rather than revenue recognition, because it has not generated product sales to date. Research and development expense is the key line item and can swing materially based on trial timing, enrollment pace, manufacturing spend, and program starts or terminations, as shown by the shift in pemvidutide and HepTcell costs. The company also relies on estimates for cash runway, accruals, and other contingent items typical of clinical-stage biopharma, where vendor invoices and trial milestones may lag the underlying work performed. Because it has significant cash and short-term investments, fair-value and classification judgments for marketable securities and liquidity disclosures are also important for investors. - **Research and development accruals** — Can materially change reported R&D expense and operating loss - **Program-specific cost allocation** — Affects trend analysis of pipeline spending - **Short-term investment valuation and liquidity disclosure** — Affects balance sheet presentation and liquidity assessment - No product revenue yet, so revenue recognition is not a major driver - R&D expense timing depends on clinical trial milestones and manufacturing spend - Program-specific costs can shift sharply when trials start, pause, or end - Accrual estimates matter for CRO, site, and vendor services not yet invoiced - Cash, cash equivalents, and short-term investments affect liquidity presentation - Share-based compensation and financing-related items can affect operating results --- *Last updated: 2026-08-11T04:46:20.187175+00:00*